BMO Capital Markets Boosts Alnylam Pharmaceuticals (ALNY) Price Target to $126.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target raised by investment analysts at BMO Capital Markets to $126.00 in a research note issued to investors on Monday, The Fly reports. BMO Capital Markets’ price objective points to a potential upside of 42.20% from the stock’s previous close.

A number of other analysts have also commented on the stock. Evercore ISI assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday. They issued an “outperform” rating and a $120.00 price objective on the stock. Leerink Swann boosted their price objective on shares of Alnylam Pharmaceuticals to $90.00 and gave the stock a “market perform” rating in a research report on Tuesday, April 9th. Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 9th. Svb Leerink boosted their price objective on shares of Alnylam Pharmaceuticals from $65.00 to $70.00 and gave the stock a “market perform” rating in a research report on Tuesday, April 9th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $135.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and sixteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $128.28.

ALNY traded down $1.20 during trading on Monday, reaching $88.61. The company had a trading volume of 213,825 shares, compared to its average volume of 702,196. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.56 and a current ratio of 6.69. Alnylam Pharmaceuticals has a 12 month low of $60.27 and a 12 month high of $124.21. The firm has a market cap of $9.81 billion, a P/E ratio of -11.71 and a beta of 2.61.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 7th. The biopharmaceutical company reported ($2.09) EPS for the quarter, topping the Zacks’ consensus estimate of ($2.27) by $0.18. The business had revenue of $21.00 million for the quarter, compared to analyst estimates of $18.03 million. Alnylam Pharmaceuticals had a negative net margin of 1,016.58% and a negative return on equity of 50.82%. The firm’s revenue for the quarter was down 44.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.20) earnings per share. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -8.68 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. ETF Managers Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 15.7% during the 4th quarter. ETF Managers Group LLC now owns 1,086 shares of the biopharmaceutical company’s stock worth $79,000 after purchasing an additional 147 shares during the period. Advisors Asset Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 0.9% during the fourth quarter. Advisors Asset Management Inc. now owns 17,883 shares of the biopharmaceutical company’s stock worth $1,304,000 after purchasing an additional 155 shares in the last quarter. M&T Bank Corp grew its holdings in Alnylam Pharmaceuticals by 3.7% during the 4th quarter. M&T Bank Corp now owns 5,305 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 188 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co grew its holdings in Alnylam Pharmaceuticals by 40.0% during the 4th quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 700 shares of the biopharmaceutical company’s stock valued at $51,000 after buying an additional 200 shares in the last quarter. Finally, Daiwa Securities Group Inc. grew its holdings in Alnylam Pharmaceuticals by 10.2% during the 4th quarter. Daiwa Securities Group Inc. now owns 3,778 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 350 shares in the last quarter. 86.88% of the stock is owned by institutional investors and hedge funds.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Recommended Story: Why is insider trading harmful?

The Fly

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply